Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4831 to 4845 of 8224 results

  1. Public transport provision and ticketing:- How effective and cost effective are changes to public transport provision and ticketing in creating and sustaining an increase in physical activity at a population level?

    Recommendation ID NG90/1 Question Public transport provision and ticketing:- How effective and cost effective are changes to public transport

    Research recommendation
    Published
    15 November 2018

  2. How effective and cost effective are different types of exercise referral scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome. Compare exercise referral schemes that vary by: - setting – for example, home-based, gym-based, community-based or outdoors - intensity and duration – for example, a 12-week scheme involving 1 session a week, or a 6-week scheme involving 4 1-hour sessions per week - the techniques used, for example, some use additional 'supportive' techniques such as 'motivational interviewing' and education sessions - the target group, for example, people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or socioeconomic status - other scheme characteristics including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it is commissioned and delivered by an NHS, non-NHS or community-based organisation.

    Recommendation ID PH54/1 Question How effective and cost effective are different types of exercise referral scheme? Compare the relative

    Research recommendation
    Published
    9 June 2015

  3. How effective and cost effective are different types of intervention to prevent a range of cold-related illnesses and death? How do these vary with groups in different circumstances?

    Recommendation ID NG6/3 Question How effective and cost effective are different types of intervention to prevent a range of cold-related

    Research recommendation
    Published
    9 June 2015

  4. Effectiveness of digital technologies:- How effective and cost effective are digital technologies, such as web-based interventions, online self-assessment or targeted new media, for drug misuse prevention among groups at risk in the UK?

    Recommendation ID NG64/5 Question Effectiveness of digital technologies:- How effective and cost effective are digital technologies, such

    Research recommendation
    Published
    4 May 2017

  5. People with limited mobility:- How effective and cost effective are environmental changes to increase physical activity among people with limited mobility because of either enduring or life-stage specific factors (for example, small children, parents with prams or buggies, disabled people including those with sensoryimpairments and learning disabilities, older people, people with dementia and their carers)? Are effects maintained over time?

    Recommendation ID NG90/4 Question People with limited mobility:- How effective and cost effective are environmental changes to increase

    Research recommendation
    Published
    15 November 2018

  6. NICE encourages the peer-reviewed publication of all further research for percutaneous balloon valvuloplasty for fetal critical aortic stenosis. Further research could be in the form of controlled trials, analysis of registry data or other observational studies. It should address patient selection, timing of the intervention and the natural history of the disease.

    Recommendation ID IPG613/1 Question NICE encourages the peer-reviewed publication of all further research for percutaneous balloon valvuloplasty

    Research recommendation
    Published
    10 December 2018

  7. NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

    Recommendation ID TA220/1 Question NICE highlighted the importance of collecting further data within registries of patients receiving biological

    Research recommendation
    Published
    9 June 2015

  8. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    Recommendation ID TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low-

    Research recommendation
    Published
    9 June 2015

  9. NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared with hypertonic saline.

    Recommendation ID TA266/1 Question NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared

    Research recommendation
    Published
    9 June 2015

  10. NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or metastatic NSCLC.

    Recommendation ID TA310/1 Question NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine

    Research recommendation
    Published
    9 June 2015

  11. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    Recommendation ID TA333/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks

    Research recommendation
    Published
    9 June 2015

  12. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with sofosbuvir in the NHS.

    Recommendation ID TA330/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks

    Research recommendation
    Published
    9 June 2015

  13. NICE recommended that further research should be designed to generate robust evidence of the clinical- and cost-effectiveness of Holoclar for treating both eyes in people with bilateral limbal stem cell deficiency after eye burns if they do not have enough tissue for a conjunctival limbal autograft. The study should recruit people with bilateral disease and evaluate the effectiveness of treatment in both eyes. Outcomes should include transplant success and assessments of health-related quality of life using a generic preference-based measure.

    Recommendation ID TA467/2 Question NICE recommended that further research should be designed to generate robust evidence of the clinical-

    Research recommendation
    Published
    15 October 2018

  14. NICE recommended that research should be carried out to determine the relationship between activity and prosthesis failure.

    Recommendation ID TA304/1 Question NICE recommended that research should be carried out to determine the relationship between activity

    Research recommendation
    Published
    9 June 2015

  15. NICE recommended the collection of data on prosthesis failure or on the prevalence of people living with a failed hip but for whom revision surgery is not suitable or who choose not to have revision surgery. NICE further recommended that nomenclature for hip replacement failure needs to be established to allow demarcation of prosthesis-dependent and prosthesisindependent hip replacement failure. Furthermore, patient reported outcome measures collected as part of the National Joint Registry should allow for reporting of hip replacement failure in people who cannot or choose not to have revision surgery.

    Recommendation ID TA304/2 Question NICE recommended the collection of data on prosthesis failure or on the prevalence of people living

    Research recommendation
    Published
    9 June 2015